Literature DB >> 26184016

A patient with esophageal cancer with bone metastasis who achieved pain relief with repetitive administration of strontium-89 chloride.

Osamu Maeda1, Takafumi Ando, Kazuhiro Ishiguro, Osamu Watanabe, Ryoji Miyahara, Masanao Nakamura, Kohei Funasaka, Kazuhiro Furukawa, Yuichi Ando, Katsuhiko Kato, Hidemi Goto.   

Abstract

A 75-year-old woman was diagnosed with esophageal cancer with difficulty in swallowing. She had a past history of rheumatoid arthritis, scleroderma, interstitial pneumonia, angina pectoris (with coronary artery bypass surgery) and arrhythmia (with pacemaker implantation). She refused surgery, and chemotherapy and radiotherapy were not performed because of the high risk accompanied with multiple comorbidities. She received proton therapy at another hospital and the primary lesion shrank. Bone metastasis in the thoracic vertebrae was diagnosed 10 months after diagnosis of esophageal cancer. Non-steroidal anti-inflammatory drugs and zoledronic acid were administered for back pain. Oxycodone was also administered but discontinued due to nausea. After strontium-89 ((89)Sr) chloride administration, her back pain was relieved. (89)Sr was administered five times every 3 months, and the pain did not worsen until her death due to pneumonia 2 years after diagnosis of esophageal cancer. (89)Sr was effective for pain from bone metastasis of esophageal cancer, and its repeated administration was safe.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 26184016     DOI: 10.1007/s12328-014-0515-1

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  15 in total

1.  Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium.

Authors:  G T Krishnamurthy; S Krishnamurthy
Journal:  J Nucl Med       Date:  2000-04       Impact factor: 10.057

Review 2.  Effective use of strontium-89 in osseous metastases.

Authors:  Isao Kuroda
Journal:  Ann Nucl Med       Date:  2011-12-13       Impact factor: 2.668

3.  (89)Sr imaging with bremsstrahlung in patients with metastatic breast cancer.

Authors:  Mana Yoshimura; Norio Kohno; Kimito Yamada; Hiroshi Kaise; Junichi Okamoto; Kenji Uchida; Tsuyoshi Hashimoto; Kiyoshi Koizumi; Koichi Tokuuye
Journal:  Clin Nucl Med       Date:  2012-11       Impact factor: 7.794

Review 4.  Radioisotopes for the palliation of metastatic bone cancer: a systematic review.

Authors:  Ilora G Finlay; Malcolm D Mason; Mike Shelley
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

5.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.

Authors:  Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin
Journal:  Int J Cancer       Date:  2010-12-15       Impact factor: 7.396

Review 6.  Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review.

Authors:  Mette H Christensen; Lars J Petersen
Journal:  Cancer Treat Rev       Date:  2011-06-16       Impact factor: 12.111

7.  Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Authors:  S M Tu; R E Millikan; B Mengistu; E S Delpassand; R J Amato; L C Pagliaro; D Daliani; C N Papandreou; T L Smith; J Kim; D A Podoloff; C J Logothetis
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

Review 8.  Strontium 89 therapy for the palliation of pain due to osseous metastases.

Authors:  R G Robinson; D F Preston; M Schiefelbein; K G Baxter
Journal:  JAMA       Date:  1995-08-02       Impact factor: 56.272

9.  Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases.

Authors:  Kimito Yamada; Mana Yoshimura; Hiroshi Kaise; Akihiko Ogata; Naoko Ueda; Koichi Tokuuye; Norio Kohno
Journal:  Exp Ther Med       Date:  2011-12-02       Impact factor: 2.447

10.  Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma.

Authors:  L E Quint; L M Hepburn; I R Francis; R I Whyte; M B Orringer
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.